An in-depth review of thalidomide's basic moieties

Thalidomide, also referred to as N-phthalimido glutarimide, was initially made available as a sedative by Chemie Grunelthal GmbH in West Germany in 1957. Thalidomide's chemical structure primarily consists of two rings: the phthalimide ring and the glutarimide ring. Although small substitutions in one or both rings might be tolerated without a reduction in toxicity, both of these groups were necessary for embryopathic action. A cyclic chemical structure that is a component of thalidomide is the phthalimide ring. The phthalimide ring is thought to contribute to both the teratogenic (causes birth defects) and some therapeutic aspects of the medication. Another cyclic structure seen in the chemical makeup of thalidomide is the Glutarimide Ring. The pharmacological characteristics of thalidomide are also connected to this portion of the molecule. Based on their activities and structural connections, this review study gives an overview of the interaction between phalidimide and the glutarimide ring for teratogenicity of the thalidomide type. Understanding how thalidomide interacts with the human body, both for its intended therapeutic effects and its negative side effects, especially when taken during pregnancy, is important given the combination of these rings in the drug's chemical structure.